In the progression of CML, the driving force is the BCR-ABL oncoprotein, which perturbs the balance of cell growth and cell death in normal hematopoietic cells and controls their malignant properties [1]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.